Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Patent expirations, FDA trial updates, and global segment revenue for Salix or Bausch + Lomb can be buried deep inside Bausch Health Companies’ disclosures. That makes a 10-K or 8-K more than a compliance form—it’s a puzzle investors must solve before patent cliffs hit cash flow. If you’ve ever scanned 300 pages searching for Xifaxan sales or litigation reserves, you know the challenge.
Stock Titan turns those dense documents into clear answers. Our AI-powered summaries flag the exact paragraphs that matter inside each Bausch Health Companies quarterly earnings report 10-Q filing and highlight Bausch Health Companies 8-K material events explained in plain language. You can monitor Bausch Health Companies insider trading Form 4 transactions, receive Bausch Health Companies Form 4 insider transactions real-time alerts, and compare compensation from the latest Bausch Health Companies proxy statement executive compensation—all without leaving this page.
Every filing type is updated the moment EDGAR posts: the Bausch Health Companies annual report 10-K simplified for pipeline risk, Bausch Health Companies earnings report filing analysis for margin trends, and understanding Bausch Health Companies SEC documents with AI for patent litigation footnotes. Need quick context? Our platform links drug-specific revenue tables, clinical milestone disclosures, and Bausch Health Companies executive stock transactions Form 4 directly to AI explanations. Access Bausch Health Companies SEC filings explained simply, download originals, or read concise takeaways designed for analysts who value both speed and depth.
Nomura Holdings filed an amended Schedule 13G reporting beneficial ownership of Bausch Health Companies Inc. common shares. Through wholly owned subsidiary Nomura Global Financial Products, Inc., the group reports beneficial ownership of 15,708,085 shares, representing 4.2% of the class.
The filing lists shared voting and dispositive power over 15,708,085 shares and no sole voting or dispositive power. The percentage is based on 370,473,221 shares outstanding as of September 30, 2025, as disclosed by the issuer. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Bausch Health Companies Inc. reported stronger Q3 2025 results. Revenue reached $2.681 billion versus $2.510 billion a year ago, and operating income rose to $619 million from $318 million. Net income attributable to Bausch Health was $179 million, compared with a loss of $85 million, translating to diluted EPS of $0.48.
For the first nine months, revenue was $7.470 billion and net income attributable to Bausch Health was $269 million with diluted EPS of $0.72. Operating cash flow was $905 million. Cash and cash equivalents were $1.308 billion, and total assets were $26.824 billion.
Debt and equity shifted due to refinancing: current portion of long-term debt decreased to $579 million from $2.674 billion, while non‑current long-term debt increased to $20.463 billion. Total equity improved to $356 million from a deficit of $(322) million at year‑end. The company acquired DURECT for $84 million, expensing $81 million as acquired IPR&D tied to Larsucosterol. Bausch + Lomb remained approximately 88% owned, and the company continues to evaluate completing the B+L separation.
Common shares outstanding were 370,516,926 as of October 24, 2025.
Amendment corrects previously reported insider holdings. This Form 4/A updates an earlier filing to state that John Paulson indirectly beneficially owned 70,755,869 common shares of Bausch Health Companies Inc. as of the 09/30/2025 transaction date. The amendment says the corrected amount matches what was reported on a prior Form 4 filed 08/14/2025 and attributes the holdings to funds managed by Paulson Capital Inc., while the reporting person disclaims direct beneficial ownership except for any pecuniary interest. The filing was signed by an attorney-in-fact on 10/06/2025.
John Paulson, a director of Bausch Health Companies Inc. (BHC), received 9,689 restricted share units on 09/30/2025 as compensation for board service for the quarter ended that date; each unit vests into one common share. After the grant, Mr. Paulson directly beneficially owns 351,128 common shares. In addition, he may be deemed an indirect beneficial owner of 32,791,702 common shares held by investment funds managed by Paulson Capital Inc., although the filing disclaims beneficial ownership except to the extent of any pecuniary interest. The transaction was reported on Form 4 and signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies director Sandra Leung was granted 3,673 restricted share units (RSUs) issued in lieu of cash compensation for her service on the board for the quarter ending September 30, 2025. Each RSU represents a contingent right to receive one common share. After the award, the reporting person beneficially owned 33,822 common shares. The transaction was reported on a Form 4 and executed under transaction code V, with the RSUs recorded at $0 price as issued units rather than an open-market purchase.
Bausch Health Companies Inc. director Amy B. Wechsler received 1,065 restricted share units on 09/30/2025 issued in lieu of cash compensation for board service. Each restricted share unit represents a contingent right to one common share and was reported as having a $0 cash price. After the grant, the reporting person beneficially owned 265,452 common shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
Bausch Health Companies Inc. disclosed a contractual mechanism tied to the company’s transaction with DURECT Corporation that grants each share a non-transferable contingent value right (CVR). The CVR represents the holder’s pro rata claim on two milestone payments that together can total up to
Seana Carson, EVP and General Counsel of Bausch Health Companies Inc. (BHC), reported two transactions in a Form 4. On 09/05/2025 the filing shows 51,337 shares were withheld to satisfy tax withholding obligations upon vesting of restricted share units at an indicated price of $7.35, leaving 512,955 shares beneficially owned. On 09/08/2025 the filing shows 13,370 shares sold in the open market pursuant to a Rule 10b5-1 plan at $7.31, reducing beneficial ownership to 499,585 shares.
The Form 4 is signed by an attorney-in-fact on behalf of the reporting person on 09/08/2025. Notes in the filing explicitly state the withholding was for tax obligations on RSU vesting and the sale was executed under a 10b5-1 plan adopted May 7, 2025.
FAQ
What is the current stock price of Bausch Health Companies (BHC)?
What is the market cap of Bausch Health Companies (BHC)?
